Anti-Venom Market Report, Industry Share, Leading Players Forecast 2023-2028

IMARC Group, a leading market research company, has recently releases report titled “Anti-Venom Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global anti-venom market share, size, growth, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Anti-venom, also known as antivenin or antivenom serum, is a specialized pharmaceutical product formulated to counteract the potentially life-threatening effects of venomous bites or stings from various creatures, such as snakes, spiders, scorpions, and other venomous organisms. It is created by extracting venom from venomous creatures and then injecting it into animals like horses or sheep in controlled doses. It is administered through injection and is specifically tailored to target venomous species. It has specific antibodies that bind to and inactivate toxins and reduce their impact on the body of the victim. It neutralizes the toxic substances found in venom and prevents from a range of adverse physiological reactions, such as tissue damage, paralysis, and even death. It saves lives and reduces hospitalization costs and long-term health complications. As it reduces the chances of morbidity and mortality associated with envenomation, the demand for anti-venom is increasing across the globe.

The global anti-venom market size reached US$ 1,096.1 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,644.9 Million by 2028, exhibiting a growth rate (CAGR) of 6.7% during 2023-2028.

Request Sample Copy of This Report:

What are the growth prospects and trends in the anti-venom industry?

At present, rising incidences of venomous bites and stings among people represent one of the key factors impelling the market growth. Moreover, the increasing focus on ethical and sustainable sourcing of venom from venomous animals is strengthening the market growth. Apart from this, the escalating demand for reliable and safe anti-venom among patients is positively influencing the market.

In addition, the rising development of more potent and safer anti-venom formulations that offer enhanced effectiveness and reduce the risk of adverse reactions in patients is contributing to the market growth. Besides this, the wide availability of anti-venom solutions in healthcare facilities around the world is supporting the growth of the market. Furthermore, the increasing awareness about the importance of early intervention in venomous encounters is providing lucrative growth opportunities to industry investors.

In line with this, the rising popularity of adventure tourism among individuals is propelling the market growth. Additionally, the increasing utilization of anti-venom in veterinary medicine to treat envenomation in animals, such as pets and livestock, is offering a favorable market outlook.

Ask Analyst for Customization and Explore Full Report with TOC & List of Figure:

What is included in market segmentation?

The report has segmented the market into the following categories:

Species Insights:

  • Snake
  • Scorpion
  • Spider
  • Others

Anti-venom Type Insights:

  • Polyvalent Anti-venom
  • Monovalent Anti-venom

Mode of Action Insights:

  • Cytotoxic
  • Neurotoxic
  • Haemotoxic
  • Cardiotoxic
  • Myotoxic
  • Others

End User Insights:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Breakup by Region:

  • North America: (United States, Canada)
  • Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America: (Brazil, Mexico, Others)
  • Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

134 N 4th St. Brooklyn, NY 11249, USA
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163